PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-04894-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Fabian Falkenbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. f.falkenbach@uke.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).
Abstract (Originalsprache)
Objective
In contrast to other malignancies, histologic confirmation prior treatment in patients with a high suspicion of clinically significant prostate cancer (csPCA) is common. To analyze the impact of extracapsular extension (ECE), cT-stage defined by digital rectal examination (DRE), and PSA-density (PSA-D) on detection of csPCA in patients with at least one PI-RADS 5 lesion (hereinafter, “PI-RADS 5 patients”). Materials and methods PI-RADS 5 patients who underwent MRI/Ultrasound fusion biopsy (Bx) between 2016 and 2020 were identified in our institutional database. Uni- and multivariable logistic-regression models were used to identify predictors of csPCA-detection (GGG ≥ 2). Risk models were adjusted for ECE, PSA-D, and cT-stage. Corresponding Receiver Operating Characteristic (ROC) curves and areas under the curve (AUC) were calculated.
Results
Among 493 consecutive PI-RADS 5 patients, the median age and PSA was 69 years (IQR 63–74) and 8.9 ng/ml (IQR 6.0–13.7), respectively. CsPCA (GGG ≥ 2) was detected in 405/493 (82%); 36/493 patients (7%) had no cancer. When tabulating for PSA-D of > 0.2 ng/ml/cc and > 0.5 ng/ml/cc, csPCA was found in 228/253 (90%, PI-RADS5 + PSA-D > 0.2 ng/ml/cc) and 54/54 (100%, PI-RADS5 + PSA-D > 0.5 ng/ml/cc). Finally, a model incorporating PSA-D and cT-stage achieved an AUC of 0.79 (CI 0.74–0.83).
Conclusion
In PI-RADS 5 patients, PSA-D and cT-stage emerged as strong predictors of csPCA at biopsy. Moreover, when adding the threshold of PSA-D > 0,5 ng/ml/cc, all PI-RADS 5 patients were diagnosed with csPCA. Therefore, straight treatment for PCA can be considered, especially if risk-factors for biopsy-related complications such as obligatory dual platelet inhibition are present.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. f.falkenbach@uke.de.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
- Department of Urology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department for Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Förderung
- Universitätsklinikum Hamburg-Eppendorf (UKE)
Zitieren
APA
Falkenbach, F., Ambrosini, F., Kachanov, M., Ortner, G., Maurer, T., Köhler, D., Beyersdorff, D., Graefen, M., & Budäus, L. (2024). PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?. World Journal of Urology. https://doi.org/10.1007/s00345-024-04894-6
Vancouver
Falkenbach F, Ambrosini F, Kachanov M, Ortner G, Maurer T, Köhler D, et al. PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?. World Journal of Urology. 2024. doi:10.1007/s00345-024-04894-6
BibTeX
@article{Falkenbach2024,
author = {Falkenbach, Fabian and Ambrosini, Francesca and Kachanov, Mykyta and Ortner, Gernot and Maurer, Tobias and Köhler, Daniel and Beyersdorff, Dirk and Graefen, Markus and Budäus, Lars},
title = {PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-04894-6}
}
EUVIMED